Molecular Partners (MOLN) has released an update.
Molecular Partners AG has unveiled promising preclinical results for MP0621, their innovative Switch-DARPin therapeutic candidate, at EHA 2024, showing its potential to enhance hematopoietic stem cell transplantation for acute myeloid leukemia. The treatment selectively targets cKit-positive cells and conditionally blocks CD47, minimizing side effects and improving the safety profile. MP0621 is advancing towards clinical testing, with expectations to begin Phase 1 trials in 2025.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.
